1. Home
  2. AMLX vs DLX Comparison

AMLX vs DLX Comparison

Compare AMLX & DLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AMLX
  • DLX
  • Stock Information
  • Founded
  • AMLX 2014
  • DLX 1915
  • Country
  • AMLX United States
  • DLX United States
  • Employees
  • AMLX N/A
  • DLX 4981
  • Industry
  • AMLX Biotechnology: Pharmaceutical Preparations
  • DLX Advertising
  • Sector
  • AMLX Health Care
  • DLX Consumer Discretionary
  • Exchange
  • AMLX Nasdaq
  • DLX Nasdaq
  • Market Cap
  • AMLX 749.9M
  • DLX 867.6M
  • IPO Year
  • AMLX 2022
  • DLX N/A
  • Fundamental
  • Price
  • AMLX $14.45
  • DLX $19.32
  • Analyst Decision
  • AMLX Strong Buy
  • DLX Strong Buy
  • Analyst Count
  • AMLX 7
  • DLX 1
  • Target Price
  • AMLX $16.86
  • DLX $23.00
  • AVG Volume (30 Days)
  • AMLX 1.9M
  • DLX 232.1K
  • Earning Date
  • AMLX 11-06-2025
  • DLX 11-05-2025
  • Dividend Yield
  • AMLX N/A
  • DLX 6.21%
  • EPS Growth
  • AMLX N/A
  • DLX 49.73
  • EPS
  • AMLX N/A
  • DLX 1.28
  • Revenue
  • AMLX N/A
  • DLX $2,106,724,000.00
  • Revenue This Year
  • AMLX N/A
  • DLX $0.20
  • Revenue Next Year
  • AMLX N/A
  • DLX $1.65
  • P/E Ratio
  • AMLX N/A
  • DLX $15.05
  • Revenue Growth
  • AMLX N/A
  • DLX N/A
  • 52 Week Low
  • AMLX $2.60
  • DLX $13.61
  • 52 Week High
  • AMLX $16.96
  • DLX $24.45
  • Technical
  • Relative Strength Index (RSI)
  • AMLX 55.78
  • DLX 56.59
  • Support Level
  • AMLX $13.88
  • DLX $17.82
  • Resistance Level
  • AMLX $16.96
  • DLX $18.81
  • Average True Range (ATR)
  • AMLX 0.99
  • DLX 0.44
  • MACD
  • AMLX -0.20
  • DLX 0.10
  • Stochastic Oscillator
  • AMLX 33.77
  • DLX 90.91

About AMLX Amylyx Pharmaceuticals Inc.

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.

About DLX Deluxe Corporation

Deluxe Corporation is principally a payments and data company. Its reportable segments are; Merchant Services, B2B Payments, Data Solutions, and Print. Maximum revenue is derived from its Print segment which provides printed personal and business checks, business essentials, as well as branded promotional, print, apparel, and digital storefront solutions. The Merchant Services segment provides electronic credit and debit card authorization, payment systems, and processing services. The B2B segment offers treasury management solutions, integrated accounts payable disbursements, and fraud and security services, and the Data Solutions segment offers data, analytics, and marketing services as well as financial institution profitability reporting and business incorporation services.

Share on Social Networks: